These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 6429731

  • 1. The Orphan Drug Act and the Federal Government's Orphan Products Development Program.
    Finkel MJ.
    Public Health Rep; 1984; 99(3):313-6. PubMed ID: 6429731
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Orphan Drug Act on congressional agenda.
    von Oehsen WH.
    Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
    [Abstract] [Full Text] [Related]

  • 4. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH.
    Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Creation and development of the public service orphan drug Human Botulism Immune Globulin.
    Arnon SS.
    Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850
    [Abstract] [Full Text] [Related]

  • 7. Orphan drug development in the United States.
    Groft SC.
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice.
    Fed Regist; 1998 Aug 05; 63(150):41855-9. PubMed ID: 10181724
    [Abstract] [Full Text] [Related]

  • 11. Development of orphan products.
    FDA Drug Bull; 1983 Apr 05; 13(1):2-4. PubMed ID: 6852406
    [No Abstract] [Full Text] [Related]

  • 12. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ.
    Prog Clin Biol Res; 1985 Apr 05; 197():11-8. PubMed ID: 4070285
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Orphan drugs: the question of products liability.
    Scharf SF.
    Am J Law Med; 1985 Apr 05; 10(4):491-513. PubMed ID: 3911776
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bioethical catch-22: the moratorium on federal funding of fetal tissue transplantation research and the NIH revitalization amendments.
    Maroney HM.
    J Contemp Health Law Policy; 1993 Apr 05; 9():485-519. PubMed ID: 10126947
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.